SOURCE: Masimo

Masimo

October 14, 2014 08:01 ET

Retrospective Study of Enhanced Recovery After Surgery Program for Patients Undergoing Colorectal Surgery, Which Included Fluid Therapy Tailored to Masimo's PVI®, Showed Reduced Length of Stay and Cost Savings

Findings Presented at American Society of Anesthesiologists Annual Meeting

IRVINE, CA--(Marketwired - Oct 14, 2014) - Masimo (NASDAQ: MASI) announced today the results of a retrospective study of an Enhanced Recovery After Surgery (ERAS) program in colorectal surgery patients, which included Masimo's PVI® monitoring.1 The ERAS program, which included fluid therapy tailored to PVI, resulted in reduced length of hospital stay, significantly reduced hospital costs, lower fluid administration, lower morphine administration, and earlier return of bowl function. The study was presented at the American Society of Anesthesiologists (ASA) Annual Meeting in New Orleans, the largest gathering of anesthesiologists in the world.

In the retrospective study of the ERAS program implemented at the University of Virginia, Dr. Robert H. Thiele and colleagues compared the results of 108 patients managed with the ERAS program to 98 consecutive patients before the ERAS program was implemented. The ERAS program included goal-directed therapy with PVI, ingestion of a carbohydrate drink two hours prior to surgery, pre-operative multimodal analgesic regimen, intraoperative low-dose spinal morphine, limiting intraoperative opiates, intraoperative infusions of ketamine and lidocaine (continued 48 hours post-operatively), early mobilization, and oral intake post-operatively.

Patients whose care was guided by the ERAS program with PVI had less fluid administered (973 ml vs 3,000 ml, p < 0.001), lower morphine equivalents (0.1 vs. 20, p < 0.001), earlier return of bowel function (p < 0.03), lower pain score (2.33 vs. 4.85, p < 0.001), fewer days of hospitalization (3 vs 5 days, P < 0.001), and lower hospital costs ($18,017 vs $15,150, P < 0.01).

The investigators concluded: "While this program includes several measures, most significantly patients received markedly less fluid and opiates in the operating room. Our program is novel in the use of PVI to guide therapy. This work highlights the importance of selection of anesthesia technique in determining outcomes for patients. Our ongoing work is in applying the lessons learned from this program to patients undergoing other types of surgery."

1 Colquhoun D, Turrentine F, Rea K, Friel C, Hedrick T, Thiele R. Implementing a Health System Wide Enhanced Recovery Program for Patients Undergoing Colorectal Surgery - The Anesthesiologists Perspective. Proceedings of the American Society of Anesthesiologists, Oct.12, 2014, New Orleans, A2010, Room 245

About Masimo
 
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow® Acoustic Monitoring, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
 
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions of the repeatability of clinical results obtained using Masimo PVI, risks related to our assumptions that PVI may help clinicians noninvasively and continuously assess fluid status of patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation

Contact Information